+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Antihypertensive Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2022-2031

  • PDF Icon

    Report

  • 213 Pages
  • June 2022
  • Region: Global
  • Transparency Market Research
  • ID: 5005275
This report on the global antihypertensive drugs market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2022 to 2031. The report provides revenue of the global antihypertensive drugs market for the period 2017-2031, considering 2021 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global antihypertensive drugs market from 2022 to 2031.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players’ product literature, annual reports, press releases, and relevant documents to understand the antihypertensive drugs market.

Secondary research also Incuded Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global antihypertensive drugs market.

The report Incudes an elaborate executive summary, along with a snapshot of the growth behavior of various segments Incuded in the scope of the study. Moreover, the report sheds light on the changing competitive dynamics in the global antihypertensive drugs market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global antihypertensive drugs market.

The report delves into the competitive landscape of the global antihypertensive drugs market. Key players operating in the global antihypertensive drugs market have been identified and each one of these has been profiled, in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are attributes of players in the global antihypertensive drugs market profiled in this report.

Research Methodology:

The research methodology will be a combination of exhaustive primary and secondary research to analyze the market antihypertensive drugs.

Secondary Research:

Secondary research Incudes a search of company literature, technical writing, patent data, Internet sources, and statistical data from government websites, trade associations, and agencies. This has proven to be the most reliable, effective, and successful approach for obtaining precise data, capturing industry participants’ insights, and recognizing business opportunities.

Secondary research sources that we typically refer, but are not limited to:

  • Company websites, presentations, annual reports, white papers, technical paper, product brochure
  • Internal and external proprietary databases and relevant patents
  • National government documents, statistical databases, and market reports
  • News articles, press releases, and webcasts specific to companies operating in the market

Specific Secondary Sources:

Industry Sources:

  • WorldWideScience.org
  • Elsevier, Inc
  • National Institutes of Health (NIH)
  • PubMed
  • NCBI
  • Department of Health Care Service

Trade Data Sources:

  • Trade Map
  • UN Comtrade
  • Trade Atlas

Company Information:

  • OneSource Business Browser
  • Hoover’s
  • Factiva
  • Bloomberg

Mergers & Acquisitions:

  • Thomson Mergers & Acquisitions
  • MergerStat
  • Profound

Primary Research:

During the course of research, we conduct in-depth interviews and discussions with a wide range of key industry participants and opinion leaders. Primary research represents bulk of research efforts, supplemented by extensive secondary research.

The publisher conducts primary interviews on the ongoing basis with industry participants and commentators to validate data and analysis.

A typical research interview fulfills the following functions:

  • Provides first-hand information on market size, market trends, growth trends, competitive landscape, outlook, etc
  • Helps in validating and strengthening secondary research findings
  • Further develops the analysis team’s expertise and market understanding
  • Primary research involves e-mail interactions, telephonic interviews, as well as face-to-face interviews for each market, category, segment, and sub-segment across geographies

Participants who typically take part in such a process Incude, but are not limited to:

  • Industry participants: Marketing/product managers, market intelligence managers, and regional sales managers
  • Purchasing/Sourcing managers, technical personnel, distributors
  • Outside experts: Investment bankers, valuation experts, and research analysts specializing in specific markets
  • Key opinion leaders specializing in different areas corresponding to different industry verticals

List of primary participants, but not limited to:

  • Advanced Oncotherapy PLC
  • Danfysik A/S
  • Hitachi, Ltd
  • IBA Worldwide
  • Mevion Medical Systems, Inc
Data Triangulation: Information culled from “Secondary & Primary Sources” is cross-checked with the publisher's 'Knowledge Repository', which is updated every quarter.

Market Estimation: Market size estimations involved in-depth study of product features, technology updates, geographic presence, product demand, sales data (value or volume), historical year-on-year growth, and others. Other approaches were also utilized to derive market size and forecasts. Where no hard data was available, we employed modeling techniques in order to produce comprehensive datasets.

A rigorous methodology has been adopted, wherein the available hard data are cross-referenced with the following data types to produce estimates:

  • Demographic Data: Healthcare expenditure, inflation rates, and others
  • Industry Indicators: R&D investment, technology stage, and infrastructure, sector growth, and facilities
Market Forecasting: Market forecasts for various segments are derived taking into account drivers, restraints/challenges, and opportunities prevailing in the market and considering advantages/disadvantages of segments/sub-segments over other segments/sub-segments. Business environment, historical sales pattern, unmet needs, competitive intensity, and country-wise surgery data are some of the other pivotal factors, which are considered to derive market forecasts.

Table of Contents

1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology3. Executive Summary: Global Antihypertensive Drugs Market
4. Market Overview
4.1. Introduction
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Antihypertensive Drugs Market Analysis and Forecast, 2017-2031
4.4.1. Market Revenue Projections (US$ Bn)
5. Market Outlook
5.1. Key Industry Developments
5.2. Impact scenario
5.3. New product developments
6. Global Antihypertensive Drugs Market Value (US$ Bn) Forecast, by Therapy Type
6.1. Introduction & Definition
6.2. Global Antihypertensive Drugs Market Value Forecast, by Therapy Type, 2017-2031
6.2.1. Diuretics
6.2.1.1. Thiazide diuretics
6.2.1.2. Loop diuretics
6.2.1.3. Potassium-sparing diuretics
6.2.2. Angiotensin Converting Enzyme Inhibitors
6.2.3. Angiotensin Receptor Blockers
6.2.4. Beta-blockers
6.2.4.1. Beta-1 Selective
6.2.4.2. Intrinsic Sympathomimetic
6.2.5. Vasodilators
6.2.6. Calcium Channel Blockers
6.2.7. Renin Inhibitors
6.2.8. Alpha-blockers
6.2.9. Others
6.3. Global Antihypertensive Drugs Market Attractiveness, by Therapy Type
7. Global Antihypertensive Drugs Market Value (US$ Bn) Forecast, by Type
7.1. Introduction & Definition
7.2. Global Antihypertensive Drugs Market Value Forecast, by Type, 2017-2031
7.2.1. Primary Hypertension
7.2.2. Secondary Hypertension
7.3. Global Antihypertensive Drugs Market Attractiveness, by Type
8. Global Antihypertensive Drugs Market Value (US$ Bn) Forecast, by Medication Type
8.1. Introduction
8.2. Global Antihypertensive Drugs Market Value Forecast, by Medication Type, 2017-2031
8.2.1. Monotherapy
8.2.2. Combination Therapy
8.2.3. Fixed Dose Combinations
8.3. Global Antihypertensive Drugs Market Attractiveness, by Medication Type
9. Global Antihypertensive Drugs Market Value (US$ Bn) Forecast, by Distribution Channel
9.1. Introduction
9.2. Global Antihypertensive Drugs Market Value Forecast, by Distribution Channel, 2017-2031
9.2.1. Retail Pharmacies
9.2.2. Hospital Pharmacies
9.2.3. Online Pharmacies
9.2.4. Others
9.3. Global Antihypertensive Drugs Market Attractiveness, by Distribution Channel
10. Global Antihypertensive Drugs Market Value (US$ Bn) Forecast, by Region
10.1. Introduction
10.2. Antihypertensive Drugs Market Value Forecast, by Region, 2017-2031
10.2.1. North America
10.2.2. Europe
10.2.3. Asia Pacific
10.2.4. Latin America
10.2.5. Middle East & Africa
10.3. Global Antihypertensive Drugs Market Attractiveness, by Region
11. North America Antihypertensive Drugs Market Analysis and Forecast
11.1. Introduction
11.2. North America Antihypertensive Drugs Market Value Forecast, by Therapy Type, 2017-2031
11.2.1. Diuretics
11.2.1.1. Thiazide diuretics
11.2.1.2. Loop diuretics
11.2.1.3. Potassium-sparing diuretics
11.2.2. Angiotensin Converting Enzyme Inhibitors
11.2.3. Angiotensin Receptor Blockers
11.2.4. Beta-blockers
11.2.4.1. Beta-1 Selective
11.2.4.2. Intrinsic Sympathomimetic
11.2.5. Vasodilators
11.2.6. Calcium Channel Blockers
11.2.7. Renin Inhibitors
11.2.8. Alpha-blockers
11.2.9. Others
11.3. North America Antihypertensive Drugs Market Value Forecast, by Type, 2017-2031
11.3.1. Primary Hypertension
11.3.2. Secondary Hypertension
11.4. North America Antihypertensive Drugs Market Value Forecast, by Medication Type, 2017-2031
11.4.1. Monotherapy
11.4.2. Combination Therapy
11.4.3. Fixed Dose Combinations
11.4.4. Others
11.5. North America Antihypertensive Drugs Market Value Forecast, by Distribution Channel, 2017-2031
11.5.1. Retail Pharmacies
11.5.2. Hospital Pharmacies
11.5.3. Online Pharmacies
11.5.4. Others
11.6. North America Antihypertensive Drugs Market Value Forecast, by Country/Sub-region, 2017-2031
11.6.1. U.S.
11.6.2. Canada
11.7. North America Antihypertensive Drugs Market Attractiveness Analysis
11.7.1. By Therapy Type
11.7.2. By Type
11.7.3. By Medication Type
11.7.4. By Distribution Channel
11.7.5. By Country/Sub-region
12. Europe Antihypertensive Drugs Market Analysis and Forecast
12.1. Introduction
12.2. Europe Antihypertensive Drugs Market Value Forecast, by Therapy Type, 2017-2031
12.2.1. Diuretics
12.2.1.1. Thiazide diuretics
12.2.1.2. Loop diuretics
12.2.1.3. Potassium-sparing diuretics
12.2.2. Angiotensin Converting Enzyme Inhibitors
12.2.3. Angiotensin Receptor Blockers
12.2.4. Beta-blockers
12.2.4.1. Beta-1 Selective
12.2.4.2. Intrinsic Sympathomimetic
12.2.5. Vasodilators
12.2.6. Calcium Channel Blockers
12.2.7. Renin Inhibitors
12.2.8. Alpha-blockers
12.2.9. Others
12.3. Europe Antihypertensive Drugs Market Value Forecast, by Type, 2017-2031
12.3.1. Primary Hypertension
12.3.2. Secondary Hypertension
12.4. Europe Antihypertensive Drugs Market Value Forecast, by Medication Type, 2017-2031
12.4.1. Monotherapy
12.4.2. Combination Therapy
12.4.3. Fixed Dose Combinations
12.4.4. Others
12.5. Europe Antihypertensive Drugs Market Value Forecast, by Distribution Channel, 2017-2031
12.5.1. Retail Pharmacies
12.5.2. Hospital Pharmacies
12.5.3. Online Pharmacies
12.5.4. Others
12.6. Europe Antihypertensive Drugs Market Value Forecast, by Country/Sub-region, 2017-2031
12.6.1. Germany
12.6.2. U.K.
12.6.3. France
12.6.4. Spain
12.6.5. Italy
12.6.6. Rest of Europe
12.7. Europe Antihypertensive Drugs Market Attractiveness Analysis
12.7.1. By Therapy Type
12.7.2. By Type
12.7.3. By Medication Type
12.7.4. By Distribution Channel
12.7.5. By Country/Sub-region
13. Asia Pacific Antihypertensive Drugs Market Analysis and Forecast
13.1. Introduction
13.2. Asia Pacific Antihypertensive Drugs Market Value Forecast, by Therapy Type, 2017-2031
13.2.1. Diuretics
13.2.1.1. Thiazide diuretics
13.2.1.2. Loop diuretics
13.2.1.3. Potassium-sparing diuretics
13.2.2. Angiotensin Converting Enzyme Inhibitors
13.2.3. Angiotensin Receptor Blockers
13.2.4. Beta-blockers
13.2.4.1. Beta-1 Selective
13.2.4.2. Intrinsic Sympathomimetic
13.2.5. Vasodilators
13.2.6. Calcium Channel Blockers
13.2.7. Renin Inhibitors
13.2.8. Alpha-blockers
13.2.9. Others
13.3. Asia Pacific Antihypertensive Drugs Market Value Forecast, by Type, 2017-2031
13.3.1. Primary Hypertension
13.3.2. Secondary Hypertension
13.4. Asia Pacific Antihypertensive Drugs Market Value Forecast, by Medication Type, 2017-2031
13.4.1. Monotherapy
13.4.2. Combination Therapy
13.4.3. Fixed Dose Combinations
13.4.4. Others
13.5. Asia Pacific Antihypertensive Drugs Market Value Forecast, by Distribution Channel, 2017-2031
13.5.1. Retail Pharmacies
13.5.2. Hospital Pharmacies
13.5.3. Online Pharmacies
13.5.4. Others
13.6. Asia Pacific Antihypertensive Drugs Market Value Forecast, by Country/Sub-region, 2017-2031
13.6.1. Japan
13.6.2. China
13.6.3. India
13.6.4. Australia & New Zealand
13.6.5. Rest of Asia Pacific
13.7. Asia Pacific Antihypertensive Drugs Market Attractiveness Analysis
13.7.1. By Therapy Type
13.7.2. By Type
13.7.3. By Medication Type
13.7.4. By Distribution Channel
13.7.5. By Country/Sub-region
14. Latin America Antihypertensive Drugs Market Analysis and Forecast
14.1. Introduction
14.2. Latin America Antihypertensive Drugs Market Value Forecast, by Therapy Type, 2017-2031
14.2.1. Diuretics
14.2.1.1. Thiazide diuretics
14.2.1.2. Loop diuretics
14.2.1.3. Potassium-sparing diuretics
14.2.2. Angiotensin Converting Enzyme Inhibitors
14.2.3. Angiotensin Receptor Blockers
14.2.4. Beta-blockers
14.2.4.1. Beta-1 Selective
14.2.4.2. Intrinsic Sympathomimetic
14.2.5. Vasodilators
14.2.6. Calcium Channel Blockers
14.2.7. Renin Inhibitors
14.2.8. Alpha-blockers
14.2.9. Others
14.3. Latin America Antihypertensive Drugs Market Value Forecast, by Type, 2017-2031
14.3.1. Primary Hypertension
14.3.2. Secondary Hypertension
14.4. Latin America Antihypertensive Drugs Market Value Forecast, by Medication Type, 2017-2031
14.4.1. Monotherapy
14.4.2. Combination Therapy
14.4.2.1. Thiazide diuretics
14.4.2.2. Loop diuretics
14.4.2.3. Potassium-sparing diuretics
14.4.3. Angiotensin Converting Enzyme Inhibitors
14.4.4. Angiotensin Receptor Blockers
14.4.5. Beta-blockers
14.4.5.1. Beta-1 Selective
14.4.5.2. Intrinsic Sympathomimetic
14.4.6. Vasodilators
14.4.7. Calcium Channel Blockers
14.4.8. Renin Inhibitors
14.4.9. Alpha-blockers
14.4.10. Others
14.5. Latin America Antihypertensive Drugs Market Value Forecast, by Type, 2017-2031
14.5.1. Primary Hypertension
14.5.2. Secondary Hypertension
14.6. Latin America Antihypertensive Drugs Market Value Forecast, by Medication Type, 2017-2031
14.6.1. Monotherapy
14.6.2. Combination Therapy
14.6.3. Fixed Dose Combinations
14.6.4. Others
14.7. Latin America Antihypertensive Drugs Market Value Forecast, by Distribution Channel, 2017-2031
14.7.1. Retail Pharmacies
14.7.2. Hospital Pharmacies
14.7.3. Online Pharmacies
14.7.4. Others
14.8. Latin America Antihypertensive Drugs Market Value Forecast, by Country/Sub-region, 2017-2031
14.8.1. Brazil
14.8.2. Mexico
14.8.3. Rest of Latin America
14.9. Latin America Antihypertensive Drugs Market Attractiveness Analysis
14.9.1. By Therapy Type
14.9.2. By Type
14.9.3. By Medication Type
14.9.4. By Distribution Channel
14.9.5. By Country/Sub-region
15. Middle East & Africa Antihypertensive Drugs Market Analysis and Forecast
15.1. Introduction
15.2. Middle East & Africa Antihypertensive Drugs Market Value Forecast, by Therapy Type, 2017-2031
15.2.1. Diuretics
15.2.1.1. Thiazide diuretics
15.2.1.2. Loop diuretics
15.2.1.3. Potassium-sparing diuretics
15.2.2. Angiotensin Converting Enzyme Inhibitors
15.2.3. Angiotensin Receptor Blockers
15.2.4. Beta-blockers
15.2.4.1. Beta-1 Selective
15.2.4.2. Intrinsic Sympathomimetic
15.2.5. Vasodilators
15.2.6. Calcium Channel Blockers
15.2.7. Renin Inhibitors
15.2.8. Alpha-blockers
15.2.9. Others
15.3. Middle East & Africa Antihypertensive Drugs Market Value Forecast, by Type, 2017-2031
15.3.1. Primary Hypertension
15.3.2. Secondary Hypertension
15.4. Middle East & Africa Antihypertensive Drugs Market Value Forecast, by Medication Type, 2017-2031
15.4.1. Monotherapy
15.4.2. Combination Therapy
15.4.3. Fixed Dose Combinations
15.4.4. Others
15.5. Middle East & Africa Antihypertensive Drugs Market Value Forecast, by Distribution Channel, 2017-2031
15.5.1. Retail Pharmacies
15.5.2. Hospital Pharmacies
15.5.3. Online Pharmacies
15.5.4. Others
15.6. Middle East & Africa Antihypertensive Drugs Market Value Forecast, by Country/Sub-region, 2017-2031
15.6.1. GCC Countries
15.6.2. South Africa
15.6.3. Israel
15.6.4. Rest of Middle East & Africa
15.7. Middle East & Africa Antihypertensive Drugs Market Attractiveness Analysis
15.7.1. By Therapy Type
15.7.2. By Type
15.7.3. By Medication Type
15.7.4. By Distribution Channel
15.7.5. By Country/Sub-region
16. Competition Landscape
16.1. Market Player - Competition Matrix (by tier and size of companies)
16.2. Company Profiles
16.2.1. Pfizer, Inc.
16.2.1.1. Company Description
16.2.1.2. Business Overview
16.2.1.3. Financial Overview
16.2.1.4. Strategic Overview
16.2.1.5. SWOT Analysis
16.2.2. Sanofi S.A
16.2.2.1. Company Description
16.2.2.2. Business Overview
16.2.2.3. Financial Overview
16.2.2.4. Strategic Overview
16.2.2.5. SWOT Analysis
16.2.3. Novartis AG
16.2.3.1. Company Description
16.2.3.2. Business Overview
16.2.3.3. Financial Overview
16.2.3.4. Strategic Overview
16.2.3.5. SWOT Analysis
16.2.4. Boehringer Ingelheim GmbH
16.2.4.1. Company Description
16.2.4.2. Business Overview
16.2.4.3. Financial Overview
16.2.4.4. Strategic Overview
16.2.4.5. SWOT Analysis
16.2.5. Actelion Ltd. (Johnson & Johnson Services, Inc.)
16.2.5.1. Company Description
16.2.5.2. Business Overview
16.2.5.3. Financial Overview
16.2.5.4. Strategic Overview
16.2.5.5. SWOT Analysis
16.2.6. F. Hoffmann-La Roche Ltd.
16.2.6.1. Company Description
16.2.6.2. Business Overview
16.2.6.3. Financial Overview
16.2.6.4. Strategic Overview
16.2.6.5. SWOT Analysis
16.2.7. Bayer AG
16.2.7.1. Company Description
16.2.7.2. Business Overview
16.2.7.3. Financial Overview
16.2.7.4. Strategic Overview
16.2.7.5. SWOT Analysis
16.2.8. Daiichi Sankyo Company, Limited
16.2.8.1. Company Description
16.2.8.2. Business Overview
16.2.8.3. Financial Overview
16.2.8.4. Strategic Overview
16.2.8.5. SWOT Analysis
16.2.9. Takeda Pharmaceutical Company Limited
16.2.9.1. Company Description
16.2.9.2. Business Overview
16.2.9.3. Financial Overview
16.2.9.4. Strategic Overview
16.2.9.5. SWOT Analysis

Companies Mentioned

A selection of companies mentioned in this report includes:

  • Pfizer, Inc.
  • Sanofi S.A
  • Novartis AG
  • Boehringer Ingelheim GmbH
  • Actelion Ltd.
  • F. Hoffmann-La Roche Ltd.
  • Bayer AG
  • Daiichi Sankyo Company, Limited
  • Takeda Pharmaceutical Company Limited